Endeavor

Moffitt Study Uncovers a Way To Boost Treatment for Aggressive Melanoma

Combination treatment triggers immune response and limits tumor growth

Moffitt Launches Immunotherapy Podcast

Monthly series highlights visionaries in immunotherapy and the breakthroughs that are transforming lives

Moffitt Study Shows New Immune Boost Could Expand Access to Cancer Immunotherapy

Adding a natural protein improves the speed and success of TIL manufacturing, potentially benefiting more patients

Collaboration and Inspiration at Heart of Society of Surgical Oncology Meeting

Surgeons who specialize in cancer care share ideas and trial data at annual meeting

Spring Swing Tour Knocks Skin Safety Out of the Park

This year’s campaign screened 115 baseball fans for skin cancer

Moffitt Experts’ Study Aims to Improve TIL Therapy Process

Tumor-infiltrating lymphocyte therapy is FDA approved to treat melanoma.

TIL Therapy for Advanced Melanoma Offers Promising Results

The study shows 36% of patients experienced a positive response to the therapy

AI Helps Predict Treatment Response in Melanoma

Identifying and analyzing immune cells under the microscope can help personalize therapies

Oral Drug Shows Potential for Advanced Melanoma Treatment

HBI-8000 combined with nivolumab shows promise in a phase 2 trial at Moffitt